185 related articles for article (PubMed ID: 33431381)
1. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.
Clift AK; Coupland CA; Hippisley-Cox J
Br J Gen Pract; 2021; 71(703):e157-e165. PubMed ID: 33431381
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
3. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Turner EL; Metcalfe C; Donovan JL; Noble S; Sterne JA; Lane JA; Avery KN; Down L; Walsh E; Davis M; Ben-Shlomo Y; Oliver SE; Evans S; Brindle P; Williams NJ; Hughes LJ; Hill EM; Davies C; Ng SY; Neal DE; Hamdy FC; Martin RM;
Br J Cancer; 2014 Jun; 110(12):2829-36. PubMed ID: 24867688
[TBL] [Abstract][Full Text] [Related]
4. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Thorn JC; Turner EL; Walsh EI; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM
BMC Health Serv Res; 2023 Jun; 23(1):610. PubMed ID: 37296430
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
7. Opportunistic prostate cancer screening: A population-based analysis.
Matti B; Zargar-Shoshtari K
Urol Oncol; 2020 May; 38(5):393-400. PubMed ID: 31952998
[TBL] [Abstract][Full Text] [Related]
8. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract][Full Text] [Related]
9. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C
BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132
[TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
12. Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Luján M; Páez Á; Angulo JC; Granados R; Nevado M; Torres GM; Berenguer A
Actas Urol Esp; 2016 Apr; 40(3):164-72. PubMed ID: 26620123
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
14. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
[TBL] [Abstract][Full Text] [Related]
15. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
17. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).
Williams NJ; Hill EM; Ng SY; Martin RM; Metcalfe C; Donovan JL; Evans S; Hughes LJ; Davies CF; Hamdy FC; Neal DE; Turner EL;
BMC Med Res Methodol; 2015 Jan; 15():6. PubMed ID: 25613468
[TBL] [Abstract][Full Text] [Related]
18. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
Li J; Zhao G; Hall IJ
Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
[TBL] [Abstract][Full Text] [Related]
19. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Pinsky PF; Prorok PC; Yu K; Kramer BS; Black A; Gohagan JK; Crawford ED; Grubb RL; Andriole GL
Cancer; 2017 Feb; 123(4):592-599. PubMed ID: 27911486
[TBL] [Abstract][Full Text] [Related]
20. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
